Literature DB >> 7127338

Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors.

K Bremer, N Niederle, W Krischke, M Higi, M E Scheulen, C G Schmidt, S Seeber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7127338     DOI： 10.1016/s0305-7372(82)80083-2

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  4 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.

Authors:  L H Einhorn
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Treatment of metastatic testicular tumours with bleomycin, etoposide, cisplatin and vincristine (BEPV).

Authors:  B A Price; N H Peters
Journal:  J R Soc Med       Date:  1992-11       Impact factor: 18.000

4.  The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).

Authors:  M J Peckham; A Barrett; K H Liew; A Horwich; B Robinson; H J Dobbs; T J McElwain; W F Hendry
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.